Scribe Therapeutics

Scribe Therapeutics specializes in genetic medicine, using CRISPR technology to develop solutions for genetic diseases. CRISPR acts like molecular scissors, allowing scientists to cut and paste DNA sequences to correct genetic defects. The company serves healthcare providers, research institutions, and pharmaceutical companies, operating in a growing market projected to reach $10.1 billion by 2026. Scribe Therapeutics develops and licenses its proprietary CRISPR-based platform, generating revenue through partnerships and technology licensing. They are also creating advanced delivery methods for in vivo genetic medicine, focusing on precise interventions that target specific gene variants, known as alleles. The goal of Scribe Therapeutics is to pioneer effective treatments for genetic diseases through precise gene editing.